October 18, 2025
Article
Postsurgical Libtayo and placebo showed similar rates of second primary tumors in high-risk CSCC
Enhertu led to a 53% reduction in the risk of invasive disease or death versus Kadcyla in some patients with high-risk, HER2-positive breast cancer.
October 17, 2025
Lenvima and Keytruda with chemo did not help patients with metastatic esophageal squamous cell carcinoma live longer than Keytruda and chemotherapy alone.
September 13, 2025
For patients with MET exon 14-altered NSCLC, Tepmetko was associated with frequent side effects, although the safety profile is considered manageable.
With Cancer, 'Your Outlook Will be Significant in Beating this Disease'
Advancing Research Offers Hope for Patients With Liver Cancer
Breast Cancer Survivor and Nurse Shares Her Story
How Breast Cancer Treatment Can Impact Menopause and Fertility